(E)-N-(tert-butyl)-3,3-dimethylbutan-2-imine | 78077-07-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (E)-N-(tert-butyl)-3,3-dimethylbutan-2-imine
• CAS: 78077-07-3
• 化学式: C₁₀H₂₁N
• 分子量: 155.283
• InChiKey: ANDDFQXFNKMTPL-DHZHZOJOSA-N

物化性质

• 沸点：
  189.2±9.0 °C(Predicted)
• 密度：
  0.76±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.29
• 重原子数：
  11.0
• 可旋转键数：
  0.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  12.36
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为产物：
  描述：

  在 (2-甲基-2-丙基)氨磺酰氯化物 、 三乙胺 作用下， 以 乙醚 为溶剂， 反应 4.0h， 生成 (E)-N-(tert-butyl)-3,3-dimethylbutan-2-imine
  参考文献：
  名称：

  Quast, Helmut; Kees, Frieder, Chemische Berichte, 1981, vol. 114, # 2, p. 774 - 786

  摘要：

  DOI：

文献信息

• Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase
  申请人：Forum Pharmaceuticals, Inc.

  公开号：US20170000749A1

  公开（公告）日：2017-01-05

  This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  这份披露涉及用于抑制组蛋白去乙酰化酶和治疗认知障碍或缺陷的化合物。更具体地，该披露提供了公式（I）的化合物 其中 Q、J、L和Z如规范中所定义。
• CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES
  申请人：ImmunoGen, Inc.

  公开号：US20160058882A1

  公开（公告）日：2016-03-03

  New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. The ansamitocin derivative-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.

  披露了带有连接基团的新型安沙米托辛衍生物。还披露了合成这些新型安沙米托辛衍生物的方法以及它们与细胞结合剂的连接方法。安沙米托辛衍生物-细胞结合剂偶联物作为治疗剂非常有用，它们能特异性地传递到目标细胞并具有细胞毒性。与先前描述的药物相比，这些偶联物在动物肿瘤模型中显示出显著提高的治疗效果。
• Inhibitors of Histone Deacetylase
  申请人：Deziel Robert

  公开号：US20080207590A1

  公开（公告）日：2008-08-28

  This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  该发明涉及用于抑制组蛋白去乙酰化酶的化合物。更具体地，该发明提供了式（I）中Q、J、L和Z所定义的化合物。
• INHIBITORS OF HISTONE DEACETYLASE
  申请人：Déziel Robert

  公开号：US20110196147A1

  公开（公告）日：2011-08-11

  This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  本发明涉及用于抑制组蛋白去乙酰化酶的化合物。更具体地，本发明提供了公式（I）中Q、J、L和Z所定义的化合物。
• METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE
  申请人：EnVivo Pharmaceuticals, Inc.

  公开号：US20150080325A1

  公开（公告）日：2015-03-19

  This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein (I), Q, J, L and Z are as defined in the specification.

  本公开涉及用于抑制组蛋白去乙酰化酶和治疗认知障碍或缺陷的化合物。更具体地，本公开提供了式(I)的化合物，其中(I)，Q，J，L和Z如规范中定义。